Financial Toxicity and Cancer

This post was written by Teri Pollastro.

Over the last several years we have heard about precision medicine, payment reform and patient-centered care. While I was at ASCO this year, I heard a new buzz word; financial toxicity. The phenomenon of financial toxicity has been whispered about for years.

Young Professionals Support Pink and Teal!

Jordan Donohue of CBRE, Inc., and Ally Goldman of WB Wood, hosted a kickoff event last week at Madison Square Tavern for the SHARE Pink and Teal Young Professionals Group! The group is enlisting young professionals in New York City's Design/Construction/Real Estate industries to support SHARE's work in educating corporate employees about breast and ovarian cancers.

Announcing New Online Support Offerings

SHARE is excited to announce its partnership with HealthUnlocked, the social network for health!
There are 2.8 million women with a history of breast cancer in the U.S. (including 155,000 women living with metastatic breast cancer), and approximately 195,000 with ovarian cancer in the United States alone.

The Status of Liquid Biopsies in Metastatic Cancer

This article was written by Joan Mancuso.

As a woman living with metastatic breast cancer, I’ve always dreaded getting a tissue biopsy of a metastasis. Even though the biopsy yields information about the tumor’s pathology and potentially affects my treatment options, I consider it a necessary evil.

Metastatic Breast Cancer Collateral Damage Project

People living with breast cancer – especially those with metastatic disease – need and deserve a better quality of life (QOL). Dr. Susan Love Research Foundation has established the Metastatic Breast Cancer Collateral Damage Project to make a significant difference for these women and men. If you have metastatic disease, please participate!

Testing In Metastatic Breast Cancer

A recent workshop given by Dr. Ruth Oratz at Living Beyond Breast Cancer’s annual conference for those living with metastatic breast cancer offered information on how oncologists use tests to determine the best course of action to treat metastatic breast cancer.

Newly Launched, TAPUR Provides Options

In mid March, American Society of Clinical Oncology (ASCO) rolled out its first clinical trial. The goal of the trial is to give us access to FDA-approved targeted drugs that match a genomic abnormality, even when the drugs have not been approved to treat metastatic breast cancer (MBC).

National Helpline: